Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Obex is a multi-ingredient dietary supplement developed by Laboratorios Catalysis, primarily indicated for the management of overweight and obesity. The formulation consists of a synergistic blend of natural extracts, including *Caralluma fimbriata* for appetite suppression, *Phaseolus vulgaris* (white kidney bean) extract to inhibit carbohydrate absorption via alpha-amylase inhibition, and Acai berry extract for its antioxidant properties. It also contains inulin to support gut health, L-carnitine to facilitate fat metabolism, and various amino acids (L-arginine, L-methionine, L-ornithine) and vitamins to improve insulin sensitivity and metabolic homeostasis. Clinical evidence from Phase III trials suggests that Obex, when combined with lifestyle modifications, significantly aids in weight loss, reduces waist circumference, and improves lipid profiles and insulin resistance markers without significant adverse effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Obex.